Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: real-world results from a single academic center in Austria

PURPOSE: IMpassion130 led to the approval of atezolizumab plus nab-paclitaxel as first-line treatment for patients with unresectable locally advanced or metastatic triple-negative, PD-L1 immune-cell positive breast cancer (BC) by the European Medicines Agency (EMA). The objective of the present stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Deutschmann, Christine, Bartsch, Rupert, Singer, Christian F, Gschwantler-Kaulich, Daphne, Seifert, Michael, Leser, Carmen, Marhold, Maximilian, Bago-Horvath, Zsuzsanna, Pfeiler, Georg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609239/
https://www.ncbi.nlm.nih.gov/pubmed/36289467
http://dx.doi.org/10.1186/s12885-022-10168-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609239/
https://www.ncbi.nlm.nih.gov/pubmed/36289467
http://dx.doi.org/10.1186/s12885-022-10168-4

Ejemplares similares